

## [147] MOSPD2: A NOVEL TARGET FOR ANTIBODY-MEDIATED KILLING OF TUMOR CELLS

### Erez Feige<sup>1</sup>, <sup>1</sup> Vascular Biogenics Ltd Operated As Vbl Therapeutics

- **Investment Rational**

VBL Therapeutics is a publicly-traded, late-stage clinical-biopharmaceutical-company focused on the discovery, development and commercialization of treatments for cancer. In addition to advancing VB-111, our anti-cancer gene-therapy agent studied in Phase 3 trial for Ovarian Cancer, VBL is developing drug candidates for the treatment of hematological cancers and solid tumors expressing the novel target protein MOSPD2.
  
- **Business Strategy**

OVAL, our Phase 3 potential registration trial for VB-111 in platinum-resistant ovarian cancer, is conducted in collaboration with the GOG Foundation, with a planned interim analysis during 1H2019. We have a strong pipeline, including our exciting MOSPD2 program for oncology and inflammatory indications, and the Lecinoxoids, our small molecules anti-inflammatory platform that supports internal development as well as strategic collaborations.
  
- **Core Technology**

VBL has pioneered the Vascular-Targeting-System, a first-in-class gene-therapy platform technology which enables systemic administration of genes to destroy or promote angiogenic blood vessels. VBL has also pioneered the Lecinoxoids platform of anti-inflammatory small-molecules and is developing MOSPD2-targeting biologics for Immune/Oncology applications. Our novel three platform technologies were developed in-house, and have broad applicability supported by strong science and IP.
  
- **Product Profile/Pipeline**

VB-111, our novel, targeted biologic IV-administered agent is in Phase 3. VB-111 has Fast-Track status and Orphan-designation in US and EU. We are also developing novel antibodies for targeting of MOSPD2+ tumor cells and for inflammatory indications. Our lead Lecinoxoid candidate VB-201, is Phase-2-ready with potential for treatment of NASH and chronic-immune-related diseases.
  
- **What's Next?**

Our Phase 3 potential-registration trial in platinum-resistant ovarian cancer is conducted in collaboration with the GOG Foundation. In parallel, we are also advancing our pipeline programs. VBL strong cash balance to support its programs through 2020.